Professor and Chairman
Department of Urology
Emory University School of Medicine
In February of 2013, Martin G. Sanda, MD, an internationally recognized prostate cancer surgeon and scientist, was appointed chair of the Department of Urology at Emory University School of Medicine and service chief for Emory Healthcare. In that capacity, he will also serve as director of the Prostate Cancer Center, which will be established within Emory’s Winship Cancer Institute.
Sanda joins Emory from Harvard Medical School, where he was professor of surgery in urology, and from Beth Israel Deaconess Medical Center, where he served as director of the Prostate Cancer Center. He was also the co-leader of the Prostate Cancer Program at the Dana Farber Cancer Center.
Sanda is principal investigator of three multi-center consortium studies funded by the National Cancer Institute and the Prostate Cancer Foundation that seek to develop urine tests for detecting prostate cancer; to develop benchmarks for improving quality of life among cancer survivors; and to develop innovative prostate cancer vaccines. These studies have enrolled over 4,400 patients with findings published in leading medical journals including the Journal of the American Medical Association and the New England Journal of Medicine.
Sanda’s clinical practice, which includes robotic prostatectomy and robotic cystectomy, is focused on developing new surgical and non-surgical approaches to cancer care and to improving the quality of life among cancer survivors.
After receiving his BA in molecular biophysics and biochemistry from Yale University cum laude in 1983, Sanda went on to receive his MD degree at Columbia University in 1987. He then trained as a general surgery resident at the Medical College of Virginia and as a surgical oncology fellow at the National Cancer Institute. He completed his urology residency at Johns Hopkins Hospital.
Sanda has served as chair of the Prostate and Genito-Urinary Collaborative Group of the National Cancer Institute’s Early Detection Research Network (2007-2010), has spearheaded two nationwide, NCI Cooperative Group prostate cancer clinical trials, has served on numerous federal funding review panels, and has served on the Research Council of the American Urological Association since 2011. Sanda has more than 150 peer-reviewed publications, and his work has been cited more than 5,000 times in biomedical literature.
BA Molecular Biophysics and Biochemistry
Yale University – Cum Laude (1979-1983)
Columbia University, New York, NY (1983-1987)
Medical College of Virginia, Richmond, VA (1987-1989)
Johns Hopkins Hospital (1991-1995)
Surgical Oncology & Immunology Fellowship
National Institute of Health, Bethesda, MD (1989-1991)
American Board of Urology (1997)
Clinical and Academic Appointments
The Johns Hopkins University (1995)
University of Michigan (1995-2003)
University of Michigan Cancer Center (1999-2003)
Beth Israel Deaconess Medical Center (2004-2013)
Dana Farber/Harvard Cancer Center (2007-2013)
Harvard Medical School (2004-2013)
Emory University School of Medicine (2013-current)